New pharmacotherapy for heart failure with reduced ejection fraction.

Sara SotirakosPeter WheenJames Paul Spiers Richard Armstrong

Published in: Expert review of cardiovascular therapy (2020)

Sacubitril/valsartan and dapagliflozin both show marked benefits on mortality in HFrEF patients. More research needs to be conducted on the mechanisms of action on disease modification.

Keyphrases

heart failure
ejection fraction
end stage renal disease
chronic kidney disease
peritoneal dialysis
cardiovascular events
prognostic factors
risk factors
cardiovascular disease
type diabetes
left ventricular
atrial fibrillation
patient reported outcomes
cardiac resynchronization therapy